Compass Pathways Plc
$ 13.54
-0.07%
07 Aug - close price
- Market Cap 1,827,214,000 USD
- Current Price $ 13.54
- High / Low $ 14.08 / 13.26
- Stock P/E N/A
- Book Value 0.62
- EPS -3.79
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -3.19 %
- 52 Week High 15.40
- 52 Week Low 3.97
About
COMPASS Pathways plc is a mental health care company in the United Kingdom and the United States. The company is headquartered in Cheshire, the United Kingdom.
Analyst Target Price
$24.06
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-13 | 2026-03-24 | 2025-11-04 | 2025-07-31 | 2025-05-08 | 2025-02-27 | 2024-10-31 | 2024-08-01 | 2024-05-08 | 2024-02-29 | 2023-11-02 |
| Reported EPS | -0.36 | -0.3 | -0.6065 | -0.38 | -0.41 | -0.42 | -0.63 | -0.56 | -0.56 | -0.55 | -0.53 | -0.67 |
| Estimated EPS | -0.46 | -0.31 | -0.3973 | -0.4 | -0.37 | -0.49 | -0.63 | -0.59 | -0.55 | -0.49 | -0.34 | -0.42 |
| Surprise | 0.1 | 0.01 | -0.2092 | 0.02 | -0.04 | 0.07 | 0 | 0.03 | -0.01 | -0.06 | -0.19 | -0.25 |
| Surprise Percentage | 21.7391% | 3.2258% | -52.6554% | 5% | -10.8108% | 14.2857% | 0% | 5.0847% | -1.8182% | -12.2449% | -55.8824% | -59.5238% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CMPS
2026-08-07 15:41:05
This article reports on a Form 144 SEC filing by COMPASS Pathways plc (CMPS) dated August 7, 2026. The filing indicates a proposed sale of 83,771 American Depositary Shares, acquired through a stock option exercise on the same date, with an aggregate market value of $1,149,152.80. The transaction is set to occur on August 7, 2026, through Fidelity Brokerage Services LLC on NASDAQ.
2026-08-07 03:41:09
This article lists various ETFs that hold COMPASS Pathways Plc Sponsored ADR stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, and performance metrics. The list is sorted by market value and aims to make investing in these stocks more accessible by offering opportunities at lower risk through diversified funds.
2026-08-07 01:10:06
Compass Pathways plc (Nasdaq: CMPS) announced its participation in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026, where management will hold a fireside chat. Additionally, the company will attend the Stifel Biotech Summit on August 10, 2026. Both events will have live audio webcasts accessible from the Investors section of Compass Pathways' website.
2026-08-06 15:39:57
Compass Pathways is collaborating with the U.S. Department of Veterans Affairs on a multi-site clinical trial for their COMP360 psilocybin treatment for veterans with treatment-resistant depression, including those with PTSD. The "PIVOT" study will evaluate different doses of COMP360, a synthetic psilocybin formulation, across five VA sites. This initiative aims to address the significant challenge of treatment-resistant depression and suicide risk among veterans.
2026-08-06 13:41:09
COMPASS Pathways reported $433 million in cash as of June 30, sufficient to fund operations through launch and into 2028, and is progressing with its NDA submission for COMP360, a psilocybin treatment for depression. Despite positive Phase III data and advancing commercial preparations, the stock fell 3.9% in premarket trading due to its pre-commercial status and uncertain launch timing. The company aims for NDA completion in Q4 2026 and a potential launch in H1 2027, with strong prescriber interest reported.
2026-08-06 13:39:57
RBC has revised its price target for COMPASS Pathways (CMPS) down to $21 from $22, while continuing to maintain an "Outperform Speculative Risk" rating on the stock. This adjustment comes amidst recent news for the biotechnology company, including other analyst rating changes and financial results. COMPASS Pathways is focused on developing psilocybin treatments for mental health conditions like treatment-resistant depression.
